These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17910204)

  • 1. Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders.
    Newcorn JH; Ivanov I
    Pediatr Ann; 2007 Sep; 36(9):564-74. PubMed ID: 17910204
    [No Abstract]   [Full Text] [Related]  

  • 2. The neurobiology of attention-deficit/hyperactivity disorder.
    Chamberlain SR; Robbins TW; Sahakian BJ
    Biol Psychiatry; 2007 Jun; 61(12):1317-9. PubMed ID: 17556026
    [No Abstract]   [Full Text] [Related]  

  • 3. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased blood pressure and atomoxetine.
    Dworkin N
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831
    [No Abstract]   [Full Text] [Related]  

  • 5. [My child is so restless].
    Schlamp D
    MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in the treatment of ADHD.
    Biederman J; Arnsten AF; Faraone SV; Doyle AE; Spencer TJ; Wilens TE; Weiss MD; Safren SA; Culpepper L
    J Clin Psychiatry; 2006 Jan; 67(1):148-59. PubMed ID: 16426101
    [No Abstract]   [Full Text] [Related]  

  • 10. Psychopharmacology of autistic spectrum disorders in children and adolescents.
    Nazeer A
    Pediatr Clin North Am; 2011 Feb; 58(1):85-97, x. PubMed ID: 21281850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective use of atomoxetine to treat six inpatient youths with disruptive mood dysregulation disorder without attention deficit disorder.
    Benarous X; Ferrafiat V; Zammit J; Consoli A; Gérardin P; Guilé JM; Cohen D
    CNS Spectr; 2020 Aug; 25(4):455-457. PubMed ID: 31218979
    [No Abstract]   [Full Text] [Related]  

  • 12. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
    Párraga HC; Párraga MI; Harris DK
    Int J Psychiatry Med; 2007; 37(4):415-24. PubMed ID: 18441629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MTA at 8.
    Pliszka SR
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1122. PubMed ID: 19855222
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of adult ADHD and comorbid disorders.
    Young JL
    CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on medication management of behavioral disorders in autism.
    Baribeau DA; Anagnostou E
    Curr Psychiatry Rep; 2014 Mar; 16(3):437. PubMed ID: 24488702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MTA at 8.
    Banaschewski T; Buitelaar J; Coghill DR; Sergeant JA; Sonuga-Barke E; Zuddas A; Taylor E;
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1120-1122. PubMed ID: 19855221
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical practice: Adult attention deficit-hyperactivity disorder.
    Volkow ND; Swanson JM
    N Engl J Med; 2013 Nov; 369(20):1935-44. PubMed ID: 24224626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
    Slatkoff J; Greenfield B
    Expert Opin Investig Drugs; 2006 Jun; 15(6):649-67. PubMed ID: 16732717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of parent reports in the MTA.
    Tryon WW
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1124. PubMed ID: 19855224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.